Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Pancreatic Cancer, Resected Clinical Trial

Official title: A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and

• Understand any possible side effects of the additional use of TG01/GM-CSF with gemcitabine

• Investigate whether TG01/GM-CSF when given with gemcitabine can produce an immune response

• Investigate if the treatment can delay or reduce recurrence of the disease

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Pancreatic Cancer, Resected
• Pancreatic Neoplasms

• NCT number: NCT02261714
• Study type: Interventional
• Source: Targovax ASA
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2012
• Completion date: May 2019